A Post-Marketing Surveillance Study of Formoterol (Foradil®)1 View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-03

AUTHORS

Lynda V. Wilton, Saad A. Shakir

ABSTRACT

Objective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice is limited. Postmarketing surveillance is particularly important at this time when medicines may be prescribed to large numbers of patients of all ages, for long-term use. Following marketing of formoterol (Foradil®) in the UK in 1996 we undertook a postmarketing surveillance study of formoterol use in general practice.Design: A non-interventional observational cohort study was conducted using the technique of prescription-event monitoring. Exposure data were obtained from prescription details; outcome data from questionnaires sent to general practitioners approximately 12 months after the first prescription was dispensed for individual patients. Incidence rates were calculated for reported events, reasons for stopping treatment and outcomes of pregnancy were determined.Results: Data were collected for 5777 patients aged 3 to 96 years, 65% of whom continued treatment for >12 months. Formoterol was prescribed ‘off label’, to 258 children, (4.5%) of the cohort. The most commonly reported events excluding those related to respiratory disease, were headache, tremor, palpitation, cramp and nausea/vomiting. These events were also among the more common reasons for stopping treatment and reported as suspected adverse drug reactions. 33 patients took formoterol during pregnancy. The cause of death was established for 186 of the 190 deaths (3% of cohort).Conclusions: Formoterol appears to have been well tolerated by the majority of patients in this study. The most frequently reported adverse events were those known to be associated with β2-agonists, although the frequency of nausea/vomiting was greater than given in Summary of Product Characteristics. More... »

PAGES

213-223

References to SciGraph publications

  • 1998-02. Formoterol in DRUGS
  • 1997-06. Treatment of asthma during pregnancy in REACTIONS WEEKLY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006

    DOI

    http://dx.doi.org/10.2165/00002018-200225030-00006

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1020065968

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/11945116


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adolescent", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adrenergic beta-Agonists", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cause of Death", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Child", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Child, Preschool", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cohort Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "England", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ethanolamines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Formoterol Fumarate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nausea", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pregnancy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pregnancy Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Product Surveillance, Postmarketing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Surveys and Questionnaires", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vomiting", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK", 
              "id": "http://www.grid.ac/institutes/grid.418589.9", 
              "name": [
                "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wilton", 
            "givenName": "Lynda V.", 
            "id": "sg:person.0720152771.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720152771.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK", 
              "id": "http://www.grid.ac/institutes/grid.418589.9", 
              "name": [
                "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shakir", 
            "givenName": "Saad A.", 
            "id": "sg:person.010623121577.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010623121577.43"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00003495-199855020-00016", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018055932", 
              "https://doi.org/10.2165/00003495-199855020-00016"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00128415-199706570-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039600874", 
              "https://doi.org/10.2165/00128415-199706570-00002"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2002-03", 
        "datePublishedReg": "2002-03-01", 
        "description": "Objective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice is limited. Postmarketing surveillance is particularly important at this time when medicines may be prescribed to large numbers of patients of all ages, for long-term use. Following marketing of formoterol (Foradil\u00ae) in the UK in 1996 we undertook a postmarketing surveillance study of formoterol use in general practice.Design: A non-interventional observational cohort study was conducted using the technique of prescription-event monitoring. Exposure data were obtained from prescription details; outcome data from questionnaires sent to general practitioners approximately 12 months after the first prescription was dispensed for individual patients. Incidence rates were calculated for reported events, reasons for stopping treatment and outcomes of pregnancy were determined.Results: Data were collected for 5777 patients aged 3 to 96 years, 65% of whom continued treatment for >12 months. Formoterol was prescribed \u2018off label\u2019, to 258 children, (4.5%) of the cohort. The most commonly reported events excluding those related to respiratory disease, were headache, tremor, palpitation, cramp and nausea/vomiting. These events were also among the more common reasons for stopping treatment and reported as suspected adverse drug reactions. 33 patients took formoterol during pregnancy. The cause of death was established for 186 of the 190 deaths (3% of cohort).Conclusions: Formoterol appears to have been well tolerated by the majority of patients in this study. The most frequently reported adverse events were those known to be associated with \u03b22-agonists, although the frequency of nausea/vomiting was greater than given in Summary of Product Characteristics.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00002018-200225030-00006", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1096281", 
            "issn": [
              "0114-5916", 
              "1179-1942"
            ], 
            "name": "Drug Safety", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "25"
          }
        ], 
        "keywords": [
          "nausea/vomiting", 
          "long-term use", 
          "surveillance study", 
          "non-interventional observational cohort study", 
          "observational cohort study", 
          "outcome of pregnancy", 
          "majority of patients", 
          "marketing surveillance study", 
          "prescription-event monitoring", 
          "adverse drug reactions", 
          "general clinical practice", 
          "cause of death", 
          "formoterol use", 
          "cohort study", 
          "first prescription", 
          "adverse events", 
          "drug reactions", 
          "general practitioners", 
          "incidence rate", 
          "individual patients", 
          "respiratory disease", 
          "\u03b22 agonists", 
          "general practice", 
          "prescription details", 
          "outcome data", 
          "common reason", 
          "prescription medicines", 
          "formoterol", 
          "clinical practice", 
          "patients", 
          "time of marketing", 
          "exposure data", 
          "vomiting", 
          "pregnancy", 
          "treatment", 
          "reported events", 
          "months", 
          "death", 
          "medicine", 
          "palpitations", 
          "headache", 
          "cramps", 
          "cohort", 
          "Foradil", 
          "disease", 
          "study", 
          "tremor", 
          "events", 
          "age", 
          "outcomes", 
          "prescription", 
          "children", 
          "surveillance", 
          "cause", 
          "questionnaire", 
          "use", 
          "majority", 
          "years", 
          "data", 
          "practice", 
          "product characteristics", 
          "summary", 
          "reasons", 
          "practitioners", 
          "time", 
          "rate", 
          "large number", 
          "experience", 
          "monitoring", 
          "UK", 
          "frequency", 
          "number", 
          "characteristics", 
          "labels", 
          "reaction", 
          "technique", 
          "detail", 
          "marketing"
        ], 
        "name": "A Post-Marketing Surveillance Study of Formoterol (Foradil\u00ae)1", 
        "pagination": "213-223", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1020065968"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00002018-200225030-00006"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "11945116"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00002018-200225030-00006", 
          "https://app.dimensions.ai/details/publication/pub.1020065968"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:23", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_359.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00002018-200225030-00006"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'


     

    This table displays all metadata directly associated to this object as RDF triples.

    242 TRIPLES      21 PREDICATES      128 URIs      118 LITERALS      29 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00002018-200225030-00006 schema:about N031b5ec7de8246eca3fbd064c6447142
    2 N053887f9a03d4677bc3a4832fd9265a0
    3 N0876dbfd9a0d4d64bd4df64f6b2aef3b
    4 N1b535b7cbdab4092b835caa34cfb6104
    5 N25c1712bac3c443591d1842401bf3d0c
    6 N3a93f3ceccf44e9e8cc6ac71e7be34d8
    7 N3cbf27b1f8ad4c6f99df8c7d6032be83
    8 N533094ef1dfe4989bf7b45a251fade57
    9 N67cb841bc1934101a6960a340508eded
    10 N7305fbd918d141a4adb0bef0e733e0c3
    11 N78b3b90b517b47f6959f87972a43ba34
    12 N7b43baaae36844b6a50d81f8cde68df3
    13 N7e7c220038db484db129bb7cb28cfbc4
    14 N9bf76c0db5254c29a4e1bca22bb08d2c
    15 N9f239cfaacbc45cda1823775cf95c04c
    16 N9fd541d7d2da4155b6b08c2aad70534c
    17 Na9e8e3925bb0498b9bf5c5dc0612af81
    18 Nbf0e92b99a5a4a99a38114a14d89d7c2
    19 Nc4b7f11559de45ae8efa1745cb21a4f3
    20 Ncf2f483dc7ab40b8918aaa7931fa5d62
    21 Nde2826d309bd4c6f8d759b6f2e463b74
    22 Ne97dd736ae7442fe93de44a77480755e
    23 anzsrc-for:11
    24 anzsrc-for:1117
    25 schema:author N609cc65931754ba0aeac9b6ef548491b
    26 schema:citation sg:pub.10.2165/00003495-199855020-00016
    27 sg:pub.10.2165/00128415-199706570-00002
    28 schema:datePublished 2002-03
    29 schema:datePublishedReg 2002-03-01
    30 schema:description Objective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice is limited. Postmarketing surveillance is particularly important at this time when medicines may be prescribed to large numbers of patients of all ages, for long-term use. Following marketing of formoterol (Foradil®) in the UK in 1996 we undertook a postmarketing surveillance study of formoterol use in general practice.Design: A non-interventional observational cohort study was conducted using the technique of prescription-event monitoring. Exposure data were obtained from prescription details; outcome data from questionnaires sent to general practitioners approximately 12 months after the first prescription was dispensed for individual patients. Incidence rates were calculated for reported events, reasons for stopping treatment and outcomes of pregnancy were determined.Results: Data were collected for 5777 patients aged 3 to 96 years, 65% of whom continued treatment for >12 months. Formoterol was prescribed ‘off label’, to 258 children, (4.5%) of the cohort. The most commonly reported events excluding those related to respiratory disease, were headache, tremor, palpitation, cramp and nausea/vomiting. These events were also among the more common reasons for stopping treatment and reported as suspected adverse drug reactions. 33 patients took formoterol during pregnancy. The cause of death was established for 186 of the 190 deaths (3% of cohort).Conclusions: Formoterol appears to have been well tolerated by the majority of patients in this study. The most frequently reported adverse events were those known to be associated with β2-agonists, although the frequency of nausea/vomiting was greater than given in Summary of Product Characteristics.
    31 schema:genre article
    32 schema:isAccessibleForFree false
    33 schema:isPartOf Nbfaf3bb239394df8ac6a37aed99e8dc1
    34 Nf26359877a4743c28916b19accd80de9
    35 sg:journal.1096281
    36 schema:keywords Foradil
    37 UK
    38 adverse drug reactions
    39 adverse events
    40 age
    41 cause
    42 cause of death
    43 characteristics
    44 children
    45 clinical practice
    46 cohort
    47 cohort study
    48 common reason
    49 cramps
    50 data
    51 death
    52 detail
    53 disease
    54 drug reactions
    55 events
    56 experience
    57 exposure data
    58 first prescription
    59 formoterol
    60 formoterol use
    61 frequency
    62 general clinical practice
    63 general practice
    64 general practitioners
    65 headache
    66 incidence rate
    67 individual patients
    68 labels
    69 large number
    70 long-term use
    71 majority
    72 majority of patients
    73 marketing
    74 marketing surveillance study
    75 medicine
    76 monitoring
    77 months
    78 nausea/vomiting
    79 non-interventional observational cohort study
    80 number
    81 observational cohort study
    82 outcome data
    83 outcome of pregnancy
    84 outcomes
    85 palpitations
    86 patients
    87 practice
    88 practitioners
    89 pregnancy
    90 prescription
    91 prescription details
    92 prescription medicines
    93 prescription-event monitoring
    94 product characteristics
    95 questionnaire
    96 rate
    97 reaction
    98 reasons
    99 reported events
    100 respiratory disease
    101 study
    102 summary
    103 surveillance
    104 surveillance study
    105 technique
    106 time
    107 time of marketing
    108 treatment
    109 tremor
    110 use
    111 vomiting
    112 years
    113 β2 agonists
    114 schema:name A Post-Marketing Surveillance Study of Formoterol (Foradil®)1
    115 schema:pagination 213-223
    116 schema:productId N1309e3b981b047e5b543233ec511d76c
    117 Nd86aeb8a226f44bbb935967e057b3a14
    118 Neb3eec5c710c4f2c8787acee0da02d36
    119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020065968
    120 https://doi.org/10.2165/00002018-200225030-00006
    121 schema:sdDatePublished 2022-12-01T06:23
    122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    123 schema:sdPublisher N4e95ecfa83524043b2eca62e429b92e0
    124 schema:url https://doi.org/10.2165/00002018-200225030-00006
    125 sgo:license sg:explorer/license/
    126 sgo:sdDataset articles
    127 rdf:type schema:ScholarlyArticle
    128 N031b5ec7de8246eca3fbd064c6447142 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name England
    130 rdf:type schema:DefinedTerm
    131 N053887f9a03d4677bc3a4832fd9265a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Formoterol Fumarate
    133 rdf:type schema:DefinedTerm
    134 N0876dbfd9a0d4d64bd4df64f6b2aef3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Female
    136 rdf:type schema:DefinedTerm
    137 N1309e3b981b047e5b543233ec511d76c schema:name dimensions_id
    138 schema:value pub.1020065968
    139 rdf:type schema:PropertyValue
    140 N1b535b7cbdab4092b835caa34cfb6104 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Aged, 80 and over
    142 rdf:type schema:DefinedTerm
    143 N25c1712bac3c443591d1842401bf3d0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Child, Preschool
    145 rdf:type schema:DefinedTerm
    146 N3a93f3ceccf44e9e8cc6ac71e7be34d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Ethanolamines
    148 rdf:type schema:DefinedTerm
    149 N3cbf27b1f8ad4c6f99df8c7d6032be83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Adolescent
    151 rdf:type schema:DefinedTerm
    152 N4e95ecfa83524043b2eca62e429b92e0 schema:name Springer Nature - SN SciGraph project
    153 rdf:type schema:Organization
    154 N533094ef1dfe4989bf7b45a251fade57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Cohort Studies
    156 rdf:type schema:DefinedTerm
    157 N609cc65931754ba0aeac9b6ef548491b rdf:first sg:person.0720152771.39
    158 rdf:rest Ncec96ecd9a2146028a240ccec1b21135
    159 N67cb841bc1934101a6960a340508eded schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Humans
    161 rdf:type schema:DefinedTerm
    162 N7305fbd918d141a4adb0bef0e733e0c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Cause of Death
    164 rdf:type schema:DefinedTerm
    165 N78b3b90b517b47f6959f87972a43ba34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Vomiting
    167 rdf:type schema:DefinedTerm
    168 N7b43baaae36844b6a50d81f8cde68df3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Adrenergic beta-Agonists
    170 rdf:type schema:DefinedTerm
    171 N7e7c220038db484db129bb7cb28cfbc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Product Surveillance, Postmarketing
    173 rdf:type schema:DefinedTerm
    174 N9bf76c0db5254c29a4e1bca22bb08d2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Aged
    176 rdf:type schema:DefinedTerm
    177 N9f239cfaacbc45cda1823775cf95c04c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Pregnancy Outcome
    179 rdf:type schema:DefinedTerm
    180 N9fd541d7d2da4155b6b08c2aad70534c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Child
    182 rdf:type schema:DefinedTerm
    183 Na9e8e3925bb0498b9bf5c5dc0612af81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Pregnancy
    185 rdf:type schema:DefinedTerm
    186 Nbf0e92b99a5a4a99a38114a14d89d7c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Nausea
    188 rdf:type schema:DefinedTerm
    189 Nbfaf3bb239394df8ac6a37aed99e8dc1 schema:volumeNumber 25
    190 rdf:type schema:PublicationVolume
    191 Nc4b7f11559de45ae8efa1745cb21a4f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Middle Aged
    193 rdf:type schema:DefinedTerm
    194 Ncec96ecd9a2146028a240ccec1b21135 rdf:first sg:person.010623121577.43
    195 rdf:rest rdf:nil
    196 Ncf2f483dc7ab40b8918aaa7931fa5d62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Adult
    198 rdf:type schema:DefinedTerm
    199 Nd86aeb8a226f44bbb935967e057b3a14 schema:name pubmed_id
    200 schema:value 11945116
    201 rdf:type schema:PropertyValue
    202 Nde2826d309bd4c6f8d759b6f2e463b74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Surveys and Questionnaires
    204 rdf:type schema:DefinedTerm
    205 Ne97dd736ae7442fe93de44a77480755e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Male
    207 rdf:type schema:DefinedTerm
    208 Neb3eec5c710c4f2c8787acee0da02d36 schema:name doi
    209 schema:value 10.2165/00002018-200225030-00006
    210 rdf:type schema:PropertyValue
    211 Nf26359877a4743c28916b19accd80de9 schema:issueNumber 3
    212 rdf:type schema:PublicationIssue
    213 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    214 schema:name Medical and Health Sciences
    215 rdf:type schema:DefinedTerm
    216 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    217 schema:name Public Health and Health Services
    218 rdf:type schema:DefinedTerm
    219 sg:journal.1096281 schema:issn 0114-5916
    220 1179-1942
    221 schema:name Drug Safety
    222 schema:publisher Springer Nature
    223 rdf:type schema:Periodical
    224 sg:person.010623121577.43 schema:affiliation grid-institutes:grid.418589.9
    225 schema:familyName Shakir
    226 schema:givenName Saad A.
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010623121577.43
    228 rdf:type schema:Person
    229 sg:person.0720152771.39 schema:affiliation grid-institutes:grid.418589.9
    230 schema:familyName Wilton
    231 schema:givenName Lynda V.
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720152771.39
    233 rdf:type schema:Person
    234 sg:pub.10.2165/00003495-199855020-00016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018055932
    235 https://doi.org/10.2165/00003495-199855020-00016
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.2165/00128415-199706570-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039600874
    238 https://doi.org/10.2165/00128415-199706570-00002
    239 rdf:type schema:CreativeWork
    240 grid-institutes:grid.418589.9 schema:alternateName Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK
    241 schema:name Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK
    242 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...